New research indicates that individuals who come off new slimming jabs like semaglutide or tirzepatide tend to recover reduced body mass much more quickly than those who end traditional lifestyle programs.
Findings released in a major medical journal demonstrates that while overweight people often shed a large proportion of their body weight while undergoing treatment, the mass comes back at an estimated rate of 0.8 kg per month upon discontinuation.
"Users using such drugs must be cognizant of the risk of fast rebound weight gain when the treatment concludes," stated expert Dr. Susan Jebb.
That rate of recovery implies a reversion to starting weight in about 18 months.
Analyzing Treatments
The analysis, which reviewed 37 of studies involving over 9,000 of participants, contrasted the effects of these new drugs with other pills.
Scientists point out that individuals who lose weight through lifestyle changes alone generally have a less rapid weight regain—approximately 100 grams monthly—once they finish.
Explaining the Quick Regain
Nutrition scientists suggest the way of the injections is key to understanding the accelerated weight return.
GLP-1 drugs imitate a body's own chemical called GLP-1, which helps regulate hunger.
"Long-term administration of GLP-1 concentrations far above than normal could lead to the system to generate a reduced amount of its own natural hormone, and may also lessen sensitivity to its effects," said Dr. Adam Collins, a dietetics expert.
"Stopping of this medication results in appetite is no longer kept in check, making overeating much more probable."
A Chronic Issue?
Health authorities recommend the jabs for people with obesity-related health risks, accompanied by prescribed lifestyle changes.
Many experts contend that, due to the significant potential of relapse, the treatment should be considered life-long.
This opinion is supported by pharmaceutical companies, who state that the findings "highlight the chronic nature of obesity," comparing it to managing conditions like hypertension.
User Experiences
People who have discontinued the jabs report a powerful return of hunger.
"It was like a trigger that goes on and you're instantly ravenous," said an individual.
The struggle is worsened if users have not established lasting lifestyle or habit changes during therapy.
Growing Interest
Survey data indicate that a significant number of people in the UK have tried weight-loss jabs in the last 12 months, with demand being substantial.
- Use is more common among females than males.
- The 40s and 50s demographic shows the greatest level of interest.
- Many access the medications through private prescriptions rather than public health services.
In conclusion, clinicians emphasize that while these medications are effective tools for weight loss, they are not a standalone cure and lasting health benefits likely depends on integrated behavioural support.
